Chimeric Therapeutics Limited announced that George Matcham has resigned as a Non-Executive Director, effective 3 August 2023. George has served on the Chimeric Board since July 2021 and has provided valued contributions to the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.016 AUD | -5.88% | -15.79% | -54.29% |
May. 22 | Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4% | MT |
May. 20 | Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-54.29% | 9.69M | |
+18.17% | 125B | |
+13.89% | 108B | |
-7.11% | 23.64B | |
+2.39% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-14.86% | 16.34B | |
+0.20% | 13.56B | |
+25.21% | 11.59B |
- Stock Market
- Equities
- CHM Stock
- News Chimeric Therapeutics Limited
- Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive Director